Very intereating?
why reduce the dosage? I assume it’s well tolerated given it’s an NK treatment.
why add more cancer indications?
this could potentially be attributed to early efficacy signals and they want to examine the therapy on broader cancer indications
- Forums
- ASX - By Stock
- Ann: 1st patient dosed in CHM 0201 Vactosertib trial
CHM
chimeric therapeutics limited
Add to My Watchlist
0.00%
!
0.4¢

Very intereating?why reduce the dosage? I assume it’s well...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $10.43K | 2.608M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 4102921 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 18587873 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 4102921 | 0.004 |
40 | 26959271 | 0.003 |
16 | 15400505 | 0.002 |
12 | 54600000 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 18587873 | 22 |
0.006 | 13384684 | 15 |
0.007 | 3100000 | 2 |
0.008 | 8542434 | 6 |
0.009 | 2390797 | 5 |
Last trade - 12.18pm 27/06/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online